Overview

BAC in Patient With Alzheimer's Disease or Vascular Dementia

Status:
Withdrawn
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of BAC patients with Alzheimer's disease or vascular dementia.The secondary objective of this study is to evaluate the safety of BAC patients with Alzheimer's disease or vascular dementia.
Phase:
Phase 2
Details
Lead Sponsor:
Charsire Biotechnology Corp.
Collaborator:
A2 Healthcare Taiwan Corporation